Cytyc Has About $180 Mil. To Invest Following Collapse Of Digene Merger
This article was originally published in The Gray Sheet
Executive Summary
Cytyc could leverage a strong cash position to expand its core women's health diagnostic business in the wake of a scuttled merger with Digene